Study of TORL-1-23 plus chemo before surgery for advanced ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new drug, TORL-1-23, given with chemotherapy before surgery for women with advanced ovarian cancer. It aims to see if this combination is safe and effective in shrinking tumors before they are removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced ovarian, primary peritoneal, or fallopian tube cancer (stage III or IV)
- Your cancer is a type called epithelial ovarian cancer (not clear cell, mucinous, or other rare types)
- Your tumor has a marker called CLDN6 (claudin 6)
- You have not had any prior chemotherapy or radiation for this cancer
- You are in good enough health to undergo surgery and treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (PD-1/CTLA-4 bispecific) combined with two chemotherapy drugs (nab-paclitaxel and carboplatin) given before surgery for advanced ovarian cancer. The goal is to shrink the tumor enough so it can be completely removed during surgery.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based treatments. The goal is to see which option works better.
This early study tests a new drug (TORL-1-23) in people with advanced solid cancers. It aims to find the safest dose and see how the tumor responds.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
Hear when a new Primary Peritoneal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.